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the presence of Rickettsia sp. in cell 
culture, and R. sibirica mongoliti-
monae was identiﬁ  ed by PCR and se-
quencing as described above (online 
Appendix Figure).
R. sibirica mongolitimonae was 
ﬁ  rst isolated in Beijing in 1991 from 
H. asiaticum ticks (formerly named 
R. sibirica HA-91), and the ﬁ  rst hu-
man infection was reported in 1996 
(4). Since that time, R. sibirica mon-
golitimonae infections have been 
diagnosed in 15 additional patients: 
12 from Europe (France, Portugal, 
Greece, and Spain) and 3 from Africa 
(Algeria, South Africa, and the pres-
ent patient who returned from Egypt). 
The application of genotypic criteria 
to R. sibirica mongolitimonae classi-
ﬁ  ed the organism as a subspecies of 
R. sibirica group, in spite of its dis-
tinct serotypes and speciﬁ  c epidemio-
logic features compared to R. sibirica 
sibirica, the causative agent of Sibe-
rian tick typhus or North Asian tick 
typhus (1).
R. sibirica mongolitimonae 
causes lymphangitis-associated rick-
ettsiosis. The available clinical fea-
tures for the only 16 reported cases 
(10 men, 6 women) include fever in all 
patients (range 38˚C–39.5°C), chills 
(3/16 patients), headache (13/16), 
myalgia (13/16), arthralgia (3/16), cu-
taneous rash (11/16), enlarged lymph 
nodes (10/16), lymphangitis expand-
ing from an inoculation eschar to 
the draining node (6/16), and retinal 
vasculitis in a pregnant woman (6,7). 
Two patients exhibited 2 eschars. 
Most eschars were on the legs, but 
some patients had an eschar on the 
back, the abdomen, the arm, or the 
face. The patients’ median age was 
50 years (range 20–76 years). A tick 
bite or tick handling was reported for 
5 patients, but no tick was collected 
for further examination. In France, 
7 patients probably came in contact 
with  R. sibirica mongolitimonae–
infected ticks in their gardens, and 2 
other patients were probably exposed 
during a walk in the Camargue Na-
tional Park, where migratory birds 
are frequently present (7). Infection 
with R. sibirica mongolitimonae oc-
curred primarily between March and 
September. A single case was report-
ed in December in Greece. R. sibirica 
mongolitimonae has been detected in 
several Hyalomma spp. ticks in Ni-
ger, Greece, the People’s Republic of 
China, Senegal, and in Rh. pusillus 
ticks in Portugal (6–8). Although Hy-
alomma spp. ticks seem to be associ-
ated with R. sibirica mongolitimonae, 
more experimental data are needed to 
determine the tick vectors and reser-
voirs of this rickettsia.
Clinicians in Egypt and those 
who may see patients returning from 
this country should be aware that sev-
eral species of rickettsiae are found in 
this region. Thus, they should consider 
a range of SFG rickettsial diseases in 
the differential diagnosis of patients 
with febrile illnesses.
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Increase in 
Neisseria 
meningitidis 
Serogroup W135, 
Niger, 2010 
To the Editor: Meningococcal 
epidemics in the African meningitis 
belt are generally caused by Neisseria 
meningitidis serogroup A strains, but 
they also can be caused by serogroup 
W135 or X strains. The largest reported 
outbreak caused by serogroup W135 
occurred in Burkina Faso in 2002 with 
≈13,000 suspected cases (1). Spo-
radic cases of meningitis caused by 
serogroup W135 have, however, been 
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detected previously, notably in Niger 
since the early 1980s (2). This sero-
group has also been associated with 
outbreaks in pilgrims to Mecca, Saudi 
Arabia, in 2000, and several clusters 
of cases occurred worldwide before 
2002 (3). After 2003, no major out-
break caused by serogroup W135 was 
detected in sub-Saharan countries, 
only sporadic cases. Although Niger 
borders Burkina Faso, Niger has not 
experienced a large outbreak of men-
ingitis caused by serogroup W135, 
with the exception of 7,906 suspect-
ed cases and 595 deaths declared in 
2001; serogroup W135 represented 
12 (38.7%) of the small number (n = 
31) of conﬁ  rmed cases (4). In 2010, 
serogroup W135 may have caused a 
major outbreak (a large proportion of 
this serogroup was detected during the 
ﬁ  rst 12 weeks). Niger residents have 
not been in contact with this serogroup 
in recent years and have never been 
immunized with the trivalent polysac-
charide vaccine (A/C/W135).
From January 1 through March 28, 
2010, the Ministry of Public Health of 
the Republic of Niger reported 1,188 
suspected cases of meningococcal dis-
ease, including 103 deaths (case-fatal-
ity rate 8.7%). Suspected cases were 
reported from all 8 provinces but pre-
dominantly in the provinces of Maradi 
(40%) and Tillabéry (24%). At week 
12, the districts of Maradi Commune 
and neighboring Madarounfa crossed 
the alert, or epidemic, threshold with 
cumulated attack rates per 100,000 
inhabitants of 57.0 and 48.5, respec-
tively. Zinder City district also crossed 
the alert threshold.
Laboratory conﬁ  rmation and mi-
crobiologic surveillance of menin-
gococcal meningitis is conducted by 
the Centre de Recherche Médicale 
et Sanitaire by using culture or PCR 
(5) techniques on cerebrospinal ﬂ  uid 
(CSF) or CSF-inoculated trans-iso-
lates. During the study period, the 
Centre received 816 CSF or trans-
isolate specimens (from 69% of the 
notiﬁ  ed cases). Culture (n = 23, 2.8%) 
and PCR (all specimens) identiﬁ  ed 
N. meningitidis as the predominant 
pathogen (n = 248, 30.4%), followed 
by Streptococcus pneumoniae (n = 35, 
4.3%) and Haemophilus inﬂ  uenzae 
(n = 13, 1.6%). Among the 248 cases 
with conﬁ  rmed meningococcal etiol-
ogy, the most frequent serogroup was 
W135 (n = 121, 48.8%), followed by 
A (n = 116, 46.8%) and X (n = 2), in-
dicating that serogroup W135 had in-
creased markedly compared with the 
past 2 years (Figure). Among the 816 
CSF specimens, 454 (56%) remained 
negative when tested for the presence 
of N. meningitidis, S. pneumoniae, or 
H. inﬂ  uenzae by PCR. Eighty-four 
(69.4%) of the serogroup W135 strains 
originated from the province of Mara-
di (southern Niger) and, more speciﬁ  -
cally, 36%.4% (n = 44) and 19.8% (n 
= 24) originated from the Madarounfa 
and Maradi districts, respectively. 
In contrast, serogroup A was mainly 
present in Tillabéry (western Niger) 
with 49.1% (n = 57) of the strains and, 
to a lesser extent, in the provinces of 
Maradi (16.4%, n = 19) and Dosso 
(13.8%, n = 16). All meningococcal 
strains (n = 9 for W135, n = 1 for A) 
recovered from trans-isolates and ana-
lyzed by Etest (AB bioMérieux, Marcy 
l’Etoile, France) were susceptible to 
beta-lactams (penicillin, amoxicillin, 
and ceftriaxone), chloramphenicol, 
and rifampin. This ﬁ  nding  supports 
the appropriateness of World Health 
Organization recommendations for 
antimicrobial drug treatment. The A 
strain belonged to the sequence type 
(ST) 7 and the W135 strains to ST 11, 
the same ST of the strain associated 
with outbreaks in pilgrims in Saudi 
Arabia in 2000 (3) and the strain that 
caused the large epidemic in Burkina 
Faso in 2002 (1).
The mean ages of patients with 
conﬁ  rmed cases of infection with se-
rogroup W135 and serogroup A were 
8.1 (SD 8.5) and 10.9 (SD 7.9) years, 
respectively. Although no signiﬁ  cant 
difference was found in the mean ages, 
the age group was 1–4 years of age 
had more disease caused by serogroup 
W135, and children 5–14 years of 
age were most affected by serogroup 
A. Similarly, the attack rate during 
the outbreak of meningitis caused by 
serogroup W135 in Burkina Faso in 
2002 was highest in patients <5 years 
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Figure. Epidemic curve of cumulative conﬁ  rmed cases of Neisseria meninigitidis serogroup 
W135 infections in Niger, 2008, 2009, and 2010 (weeks 1–12). No cases were found in 
2008. A color version of this ﬁ   gure is available online (www.cdc.gov/EID/content/16/9/
1496-F.htm).
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of age, and the attack rate decreased as 
patients’ ages increased (6).
Reactive vaccination campaigns 
in some communes of Madarounfa 
district that had reached the epidemic 
threshold were launched by the Minis-
try of Public Health with a remaining 
2009 stockpile (16,527 doses, 35.7% 
coverage) of the quadrivalent polysac-
charide vaccine (A/C/Y/W135) from 
Médecins sans Frontières. The Interna-
tional Coordinating Group on Vaccine 
Provision for Epidemic Meningitis 
Control has also recently approved the 
release of 381,526 doses of trivalent 
polysaccharide vaccine (A/C/W135) 
for vaccination campaigns in Maradi 
and Zinder districts. Future immuniza-
tion campaigns will be implemented 
by Ministry of Public Health with the 
support of the World Health Organiza-
tion and partners, including Médecins 
sans Frontières and The United Na-
tions Children’s Fund.
Given the large population at 
risk, and the low availability and high 
cost of the trivalent vaccine, a sound 
vaccination strategy is of particular 
importance to mitigate the expansion 
of serogroup W135 in the country. 
Microbiologic surveillance is critical 
in the early and accurate detection of 
meningococcal serogroups for deter-
mining the appropriate vaccine. 
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Toscana Virus 
Infection in 
American Traveler 
Returning from 
Sicily, 2009 
To the Editor: Since the discov-
ery of Toscana virus (TOSV) in 1971 
in Tuscany (1), sandﬂ  y-borne TOSV 
has become recognized as a leading 
cause of acute meningitis in central 
Italy during the summer (2). France, 
Spain, Portugal, Greece, and Cyprus 
have also reported cases of TOSV in-
fection (2). Although TOSV has been 
detected in sandﬂ  ies in Sicily (3), we 
are not aware of any historically docu-
mented human infection with TOSV 
in this southernmost region of Italy.
We report TOSV infection of an 
American male physician, 65 years of 
age, who traveled to Sicily for 3 weeks 
and returned to the United States in 
October 2009. Two days after his re-
turn, he awoke with a headache, and 
hours later he noticed difﬁ  culty ﬁ  nd-
ing words. His headache progressed, 
and during the next few hours, he 
experienced severe expressive dys-
phasia. At admission to the hospital, 
he denied having fever, nuchal rigid-
ity, photophobia, nausea, vomiting, or 
diarrhea.
Other than changing planes in Mi-
lan, the patient had remained in Sicily 
during the entire 3 weeks of his visit. 
He had sustained both mosquito and 
what he thought were ﬂ  ea bites while 
in Sicily. He had no known exposure 
to bats, rabid animals, or ticks.
Computed tomographic scan and 
magnetic resonance imaging of the 
brain showed no mass lesions or ab-
normality of the cerebral vessels. A 
sample of cerebrospinal ﬂ  uid  (CSF) 
obtained at admission showed 14 
leukocytes/mm3 (reference range 0–5 
leukocytes/mm3) with 100% lympho-
cytes, a protein level of 126 mg/dL 
(reference range 15–45 mg/dL), and a 
glucose level of 63 mg/dL (reference 
range 50–80 mg/dL). A nasopharyn-
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